Results 181 to 190 of about 57,488 (195)

Integrated molecular characterization of IDH-mutant glioblastomas

Neuropathology and Applied Neurobiology, 2019
Felix Sahm, Marina Ryzhova, Andrey Golanov   +2 more
exaly  

Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI

Magnetic Resonance in Medicine, 2017
Zhibo Wen, Tianyu Zou
exaly  

INHIBITING MUTANT IDH-1

2021
KELLY PATRICK F, COLLIS ALAN, DAVIS JEFF, WALKER DUNCAN, ASHWELL SUSAN, THOMSON BLYTHE, WEI LU   +6 more
openaire   +4 more sources

Heterogeneous response of IDH-mutant and IDH-WT glioma to NAMPT inhibition

2020
Masum Rahman, Hirte, Renee, Olson, Ian E, Mansour, Moustafa A, Jibo Zhang, Ikram, Samar, Saber, Rehan, Rujapope Sutiwisesak, Muñoz-Casabella, Amanda, Carlstrom, Lucas P, Warrington, Arthur, Karishma Rajani, Sarkaria, Jann, Burns, Terry C   +13 more
openaire   +1 more source

IDH mutated gliomas

Journal of the Neurological Sciences, 2021
openaire   +1 more source

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles

Cell Reports, 2017
Rameen Beroukhim, Tushar Patel, Marco Marra   +2 more
exaly  

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions

Pharmacology & Therapeutics, 2017
Amir Fathi, Andrew M Brunner
exaly  

Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH-mutated anaplastic glioma

Ca-A Cancer Journal for Clinicians
Carrie Printz
exaly  

Characterization of a mutation in the IDH-II subunit of the NAD-dependent isocitrate dehydrogenase from

Plant Science, 2004
David J Oliver
exaly  

[Ⅳ. IDH Inhibitor].

Gan to kagaku ryoho. Cancer & chemotherapy, 2022
Fumiya, Wada, Tadakazu, Kondo
openaire   +1 more source